CIK 0001437402
- Large accelerated filer
ARDELYX, INC.
Sign in to watch- Ticker
- ARDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 510-745-7047
- Business address
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Former names
- NTERYX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $486,197
- in 8 filings
Net −$486,197. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- RAAB MICHAEL −$226K President & CEO sold 3% of stake
- Bishop John E −$76K Reporting owner sold 6% of stake
- Brady James Parker −$58K Chief Human Resources Officer sold 6% of stake
- Williams Laura A −$41K Chief Patient Officer sold 3% of stake
- Foster Eric Duane −$33K Chief Commercial Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-20 | Blanks Robert | Sale | −4,969 | $5.86 | $29K | 319,362 |
| 2024-08-20 | Rosenbaum David P. Chief Development Officer | Exercise or conversion 10b5-1 | +20,507 | $0.99 | $20K | 179,009 |
| 2024-08-20 | Rosenbaum David P. Chief Development Officer | Sale 10b5-1 | −20,507 | $6.00 | $123K | 158,502 |
| 2024-08-20 | Rosenbaum David P. Chief Development Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −20,507 | 49,806 | ||
| 2024-08-16 | Rosenbaum David P. Chief Development Officer | Sale 10b5-1 | −20,000 | $5.94 | $119K | 356,479 |
| 2024-08-12 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −1,229 | $5.71 | $7K | 1,259,234 |
| 2024-08-08 | Foster Eric Duane Chief Commercial Officer | Grant or award | +180,000 | 180,000 | ||
| 2024-08-08 | Foster Eric Duane Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +230,000 | 230,000 | ||
| 2024-07-29 | RAAB MICHAEL President & CEO | Exercise or conversion 10b5-1 | +30,000 | $0.99 | $30K | 1,290,463 |
| 2024-07-29 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −30,000 | $5.64 | $169K | 1,260,463 |
| 2024-07-29 | RAAB MICHAEL President & CEO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −30,000 | 605,000 | ||
| 2024-07-15 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −7,500 | $5.97 | $45K | 1,260,463 |
| 2024-06-28 | RAAB MICHAEL President & CEO | Sale 10b5-1 | −2,310 | $6.59 | $15K | 1,267,963 |
| 2024-06-21 | Blanks Robert | Sale 10b5-1 | −38,000 | $5.96 | $226K | 324,331 |
| 2024-06-14 | Rodgers Richard J Director | Grant or award | +12,204 | 250,524 | ||
| 2024-06-14 | Rodgers Richard J Director | Grant or award · Stock Option (Right to Buy) | +40,243 | 40,243 | ||
| 2024-06-14 | Bhanji Muna Director | Grant or award · Stock Option (Right to Buy) | +40,243 | 40,243 | ||
| 2024-06-14 | Bertrand William C JR Director | Grant or award | +11,023 | 229,766 | ||
| 2024-06-14 | Bertrand William C JR Director | Grant or award · Stock Option (Right to Buy) | +40,243 | 40,243 | ||
| 2024-06-14 | Cadoret-Manier Onaiza Director | Grant or award · Stock Option (Right to Buy) | +40,243 | 40,243 |
Page 13 of 18 · 360 trades